Parexel International has formed an alliance with National Taiwan University Hospital (NTUH) to provide drug development services in Taiwan.
Partnering with NTUH will further enhance Parexel’s ability to meet rising client demand for a full range of Phase I-IV clinical trials in a “rapidly growing market”, said Dr Joe Avellone, corporate senior vice president, Clinical Research Services for the US-based biopharmaceutical services provider.
According to Avellone, the hospital is “well-known and highly respected” in Taiwan. It is also, Parexel noted, a centre of excellence for clinical trials in Taiwan and the Asia-Pacific region.
As such, the company added, NTUH is ideally placed to support Parexel in delivering a superior clinical-development service to both local and global biopharmaceutical companies.
“The combined experience and development expertise of the two organisations will help to create innovative solutions for biopharmaceutical companies looking to develop or market their products within this important region,” Parexel stated.